Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Randomized, Double-blind, Placebo-controlled Study Followed by a Treatment Extension to Evaluate the Efficacy and Safety of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1

This study will be conducted to evaluate the efficacy and safety of YOLT-203 in children and adults with Primary Hyperoxaluria Type 1. After the initial rando…

Primary Hyperoxaluria Type 1PH1

Estimated

~$10 – $8,750

YolTech Therapeutics Co., LtdNCT07587021

Rare Kidney Stone Consortium Biobank, Rare Diseases Clinical Research Network

This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent…

Primary HyperoxaluriaDent DiseaseAPRT Deficiency+1 more

Estimated

~$10 – $750

Mayo ClinicNCT02026388

Rare Kidney Stone Consortium Registry for Hereditary Kidney Stone Diseases

The purpose of this study is to collect medical information from a large number of patients in many areas of the world with primary hyperoxaluria (PH), Dent di…

Primary HyperoxaluriaDent DiseaseCystinuria+1 more

Estimated

~$10 – $750

Mayo ClinicNCT00588562

Phase 2

A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis

The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.

Primary Hyperoxaluria Type 1End Stage Renal Disease

Estimated

~$10 – $8,750

Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyNCT04580420

Phase 1

A Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Participants With Primary Hyperoxaluria Type 1 (PH1)

The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperox…

Primary Hyperoxaluria Type 1 (PH1)

Estimated

~$10 – $8,750

Arbor BiotechnologiesNCT06839235